No abstract available.
Phototherapy*

No abstract available.
Phototherapy*

No abstract available.
Calcium* ; Phototherapy*

Introduction: Narrowband ultraviolet B (NBUVB) phototherapy is a well-established treatment option for a variety of dermato- logic conditions. The initial dosage is obtained either by determining the patients’ minimal erythema dose (MED) or their Fitzpat- rick skin phototype (SPT). MED determination is a better way to establish the proper initial dose as it is more objective. However, in practice, SPT is more commonly used as it is more convenient, and MED data in Filipinos are scarce. Objectives: To establish data determining the MED values of Filipino adults that can serve as a basis to standardize the initial dose of NBUVB phototherapy in a tertiary hospital. Methods: We enrolled 86 volunteers in a cross-sectional analytical study to determine their MED and assess if there is any asso- ciation between their MED and the participants’ age, sex, skin prototype, ancestry, and daily duration of sun exposure. Results: The median MED of the participants is 800 mJ/cm2 (IQR 600-800 mJ/cm2 ). A majority of 38 participants (44.19%) have a MED of 800mJ/cm2 followed by 600mJ/cm2 for 23 (26.74%) participants. There was also a significant association between study partici- pants’ MED with respect to their Fitzpatrick skin type (p=<0.001) and ancestry (p=0.03), but with no association with regards to age (p=0.291), sex (p=0.245), and daily duration of sun exposure (p=0.237). Conclusion Majority of the participants have a median MED value of 800 mJ/cm2. Based on this MED value, the initial dosage of NBUVB at 50-70% of the MED would translate to an initial dose of 400-560 mJ/cm2.
Erythema ; Phototherapy

We performed anthralin comparative study(0.01% vs 0.1%) to assess the effectiveness of low-strengh anthralin therapy in 34 psoriatic patients and the resu1ts can be summarized as follows. 1. In the case of 13 patients using Burdick UVB larnp, in 1 patient the effect of 0.1% anthralin was superior to that of 0.01% anthralin from the start to the end of treatment, in 5 patients(38.5%) initially the effect of 0.1% anthralin was superior but in time became equal to that of 0.01% anthralin, and in 7 patients (53.8%) the effect of either side was same throughout the courae of the treatment. In the case of 21 patients using Waldmann UVB cabinet, there were 2(9.5 %), 3(14.3%) and 16 patients(76.2%) in the order named above. 2. The side effect of 0.1% anthralin was more severe than or at least the same as that of 0.01% anthralin in every patient who complained about side effects. So low-strengh anthalin-UVB phototherapy was thought to be the effective and alternative method of treatment particularly for the purpose of lessening the side effects.
Anthralin* ; Humans ; Phototherapy ; Psoriasis*

No abstract available.
Hyperbilirubinemia, Neonatal* ; Phototherapy*

BACKGROUND: Narrow-band UVB phototherapy using 311+-2nm wavelength is in widespread use due to its greater efficacy and, possibly, safety compared with broad-band UVB sources. OBJECTIVE: We performed emollient narrow-band UVB(NBUVB) phototherapy to evaluate the clinical efficacy and safety in Korean psoriasis patients. METHODS: Fifteen psoriasis patients received narrow-band UVB phototherapy. We categorized each patient into clearing, improvement, or failure groups based on the therapeutic efficacy, and measured the PASI score every two weeks. RESULTS: 1. Among patients who received narrow-band UVB phototherapy, clearing was shown in 40.0% and improvement in 27.7%, and failure in 33.3%. 2. The total number, duration, final and cumulative doses to achieve grade IV were 16.3, 39 days, 1,050mJ/cm2 and 12,125mJ/cm2 respectively. 3. There were some side effects of NBUVB phototherapy such as pruritus(53.3%) and mild burning(13.3%). CONCLUSION: Narrow-band UVB phototherapy is a effective treatment modality which is convenient and less erythemogenic in psoriasis. It will be used more and more and play an important role in the treatment of psoriasis.
Humans ; Phototherapy* ; Psoriasis*

BACKGOUND: Narrow-band ultraviolet B (NBUVB) phototherapy has appeared to be effective in clearing psoriatic lesions. Calcipotriol has been combined with a number of the systemic antipsoriatic treatments, improving efficacy or reducing the systemic treatment required. OBJECTIVE: We performed calcipotriol-NBUVB combination therapy to evaluate the clinical efficacy and the safety in Korean psoriasis patients. METHOD: In the psoriasis clinic at Seoul National University Hospital, 69 psoriasis patients were treated with calcipotriol-NBUVB. Phototherapy was given once daily, three times a week, and the dose was gradually increased. Calcipotriol ointment was applied twice a day. The PASI score was used to evaluate the effects of the treatment and the patients were classified according to clearance, improvement, or failure. RESULTS: The therapeutic results showed 53.6% for clearance, 31.9% for improvement and 14.5% for failure. The total number, duration, final and cumulative doses to achieve grade IV were 16.1, 41.8days, 1487.3mJ/cm2, and 15234.5mJ/cm(2) respectively. Of 69 patients, 44 patients experienced variable adverse effects, but there was no significant adverse effect to discontinue the therapy. CONCLUSION: Our results demonstrated that using calcipotriol ointment with NBUVB phototherapy is an effective therapeutic method for psoriatic patients.
Humans ; Phototherapy* ; Psoriasis ; Seoul

Acquired reactive perforating collagenosis (ARPC) is difficult to treat. We herein report 3 cases of ARPC, which have been improved by narrowband UVB phototherapy. They had been treated with topical corticosteroid and oral antihistamine, which had no therapeutic effects on their conditions. They were treated with narrowband UVB phototherapy twice a week and four-week treatments resulted in relief of pruritus in three patients and eight-week treatments lead to significant reduction of skin lesions in two patients. Based on our experience, it is suggested that narrowband UVB phototherapy is a good therapeutic modality for recalcitrant skin lesions and severe pruritus of ARPC.
Humans ; Phototherapy* ; Pruritus ; Skin

Progressive macular hypomelanosis is an idiopathic acquired hypopigmentary disorder first described in 1988. The disorder is characterized by ill-defined, non-scaly, round to oval, hypopigmented patches symmetrically localized on the trunk. No clinical symptoms have been observed. Currently, diagnosis is made on clinical grounds and any histological, laboratory investigations are not diagnostic. This disorder does not respond to conventional treatment and its clinical course is variable. We experienced a case of progressive macular hypomelanosis that was successfully treated with narrow band UVB phototherapy.
Diagnosis ; Hypopigmentation* ; Phototherapy